Annette Whittemore (not to be confused with Vicky Whittemore) is a patient advocate and the mother of a daughter, Andrea Whittemore-Goad, who has been sick with ME since she was a pre-teen. She was fundamental in establishing the research institute Whittemore Peterson Institute.
According to Ms. Whittemore's Linkedin page, her commitment to helping her daughter and others with similar illnesses is well documented:
- "1989 Began the search for knowledge and treatment for a young daughter's serious illness.
- 2001: Co-sponsored a CFS Think Tank for physicians and allied health professionals in Reno, Nevada.
- 2003: Supported amended Assembly Bill 502 in the Nevada State legislature requiring insurance companies in Nevada to provide coverage for medical treatment when part of a clinical trial in phase II, phase III, and phase IV, for patients with cancer and chronic fatigue syndrome (CFS), myalgic encephalomyelitis, ME/CFS.
- 2004: Co-founded the HHV-6 Foundation
- 2005: Successfully sought seed funding for a 70 million dollar joint medical research building project for the University of Nevada, Reno, Nevada Cancer Institute and the WPI
- 2006: Created the Neuro-Immune Research Foundation which became the foundation of support for WPI
- 2007: Successfully sought additional funding for building and operations for the Whittemore Peterson Institute."
In 2016, the Whittemore Peterson Institute changed its name to the Nevada Center for Biomedical Research.
In January 2019, due to restructuring of the research program, the center returned to its original name, the Whittemore Peterson Institute.
Awards[edit | edit source]
- 2006, Health Care Hero Award, Nevada Business Journal(p18)
- 2008, University of Nevada, Alumna of the Year
- 2009, IACFS/ME Special Service Award - for outstanding personal effort and contribution to the CFS/ME community </ref>
- 2009, Honorary Doctor of Letters, University of Nevada, Reno
Talks and interviews[edit | edit source]
- 2007, Speaker at the 2nd Invest in ME International ME Conference - Speech title: A Model ME/CFS Clinic - The CFS Clinic – Reno, Nevada, US - (Video)
- 2010, Speaker at the 5th Invest in ME International ME Conference - Speech title: Future Pathways of Research into ME
- 2011, Keynote Speaker at the 6th Invest in ME International ME Conference - Speech Title: Translating ME/CFS Research into Treatments
- 2011, 10th International IACFSME Conference, Patient Agenda - Speech title: "Translating Scientific Research into Patient Care"
- 2011, ME/CFS Alert - Episode 04 - Annette Whittemore, President of the Whittemore Peterson Institute
See also[edit | edit source]
References[edit | edit source]
- Johnson, Cort (April 20, 2008). "Annette Whittemore and the Making of the Whittemore Peterson Institute in Reno". Prohealth. Retrieved February 19, 2020.
- "The 'April Surprise'". Phoenix Rising ME / CFS Forums. Retrieved February 19, 2020.
- Cohen, Jon (January 30, 2012). "Lawsuit Alleges Misuse of Funds by Founders of Whittemore Peterson Institute". Science | AAAS. Retrieved February 19, 2020.
- WPI. "NVCBR Latest News". Whittemore Peterson Institute. Retrieved January 17, 2019.
- "Whittemore named University's Alumna of the Year". University of Nevada, Reno. Retrieved February 21, 2020.
- "IACFS/ME Awardees". IACFS/ME. Retrieved April 23, 2020.
- Whittman Institute (February 19, 2020). "About | Executive Staff". wpinstitute.
- "Invest in ME Research - IIMEC4". Invest in ME Research. Retrieved February 19, 2020.
- "Invest in ME Research - IIMEC5 International ME Conference 2010". Invest in ME Research. Retrieved February 19, 2020.
- "Invest in ME Research - IIMEC6 International ME Conference 2011". Invest in ME Research. Retrieved February 19, 2020.
phase two A trial involve patients to assess side effects and effectiveness for a particular clinical condition. Typically 100-300 patients.
phase three Last phase of clinical trials before a drug can be approved for public use. Whereas Phase one assesses basic safety, and Phase two assesses basic efficacy, Phase three uses many trial participants to fully assess both safety and efficacy, and overall benefit/risk.